Cargando…
Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation
The adrenal glands participate in cardiovascular (CV) physiology and the pathophysiology of CV diseases through their effects on sodium and water metabolism, vascular tone and cardiac function. In the present study, we identified a new adrenal compound controlling mesenchymal cell differentiation th...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514386/ https://www.ncbi.nlm.nih.gov/pubmed/34647168 http://dx.doi.org/10.1007/s00395-021-00899-z |
_version_ | 1784583370254057472 |
---|---|
author | Orth-Alampour, Setareh Gayrard, Nathalie Salem, Silvia Bhargava, Shruti Jankowski, Vera Jover, Bernard Notarnicola, Cécile Noels, Heidi van der Vorst, Emiel P. C. Kuppe, Christoph Wolf, Michael Goettsch, Claudia Theelen, Wendy Bruck, Heike Fliser, Danilo Loscalzo, Joseph Wu, Zhuojun Marx, Nikolaus Zidek, Walter Argilés, Àngel Jankowski, Joachim |
author_facet | Orth-Alampour, Setareh Gayrard, Nathalie Salem, Silvia Bhargava, Shruti Jankowski, Vera Jover, Bernard Notarnicola, Cécile Noels, Heidi van der Vorst, Emiel P. C. Kuppe, Christoph Wolf, Michael Goettsch, Claudia Theelen, Wendy Bruck, Heike Fliser, Danilo Loscalzo, Joseph Wu, Zhuojun Marx, Nikolaus Zidek, Walter Argilés, Àngel Jankowski, Joachim |
author_sort | Orth-Alampour, Setareh |
collection | PubMed |
description | The adrenal glands participate in cardiovascular (CV) physiology and the pathophysiology of CV diseases through their effects on sodium and water metabolism, vascular tone and cardiac function. In the present study, we identified a new adrenal compound controlling mesenchymal cell differentiation that regulates osteoblastic differentiation in the context of vascular calcification. This peptide was named the “calcification blocking factor” (CBF) due to its protective effect against vascular calcification and is released from chromogranin A via enzymatic cleavage by calpain 1 and kallikrein. CBF reduced the calcium content of cells and thoracic aortic rings under calcifying culture conditions, as well as in aortas from animals treated with vitamin D and nicotine (VDN animals). Furthermore, CBF prevented vascular smooth muscle cell (VSMC) transdifferentiation into osteoblast-like cells within the vascular wall via the sodium-dependent phosphate transporter PIT-1 and by inhibition of NF-κB activation and the subsequent BMP2/p-SMAD pathway. Pulse pressure, a marker of arterial stiffness, was significantly decreased in VDN animals treated with CBF. In line with our preclinical data, CBF concentration is significantly reduced in diseases characterized by increased calcification, as shown in patients with chronic kidney disease. In preparation for clinical translation, the active site of the native 19-AS long native CBF was identified as EGQEEEED. In conclusion, we have identified the new peptide CBF, which is secreted from the adrenal glands and might prevent vascular calcification by inhibition of osteogenic transdifferentiation. The anti-calcific effects of CBF and short active site may therefore promote the development of new tools for the prevention and/or treatment of vascular calcification. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00395-021-00899-z. |
format | Online Article Text |
id | pubmed-8514386 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-85143862021-10-27 Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation Orth-Alampour, Setareh Gayrard, Nathalie Salem, Silvia Bhargava, Shruti Jankowski, Vera Jover, Bernard Notarnicola, Cécile Noels, Heidi van der Vorst, Emiel P. C. Kuppe, Christoph Wolf, Michael Goettsch, Claudia Theelen, Wendy Bruck, Heike Fliser, Danilo Loscalzo, Joseph Wu, Zhuojun Marx, Nikolaus Zidek, Walter Argilés, Àngel Jankowski, Joachim Basic Res Cardiol Original Contribution The adrenal glands participate in cardiovascular (CV) physiology and the pathophysiology of CV diseases through their effects on sodium and water metabolism, vascular tone and cardiac function. In the present study, we identified a new adrenal compound controlling mesenchymal cell differentiation that regulates osteoblastic differentiation in the context of vascular calcification. This peptide was named the “calcification blocking factor” (CBF) due to its protective effect against vascular calcification and is released from chromogranin A via enzymatic cleavage by calpain 1 and kallikrein. CBF reduced the calcium content of cells and thoracic aortic rings under calcifying culture conditions, as well as in aortas from animals treated with vitamin D and nicotine (VDN animals). Furthermore, CBF prevented vascular smooth muscle cell (VSMC) transdifferentiation into osteoblast-like cells within the vascular wall via the sodium-dependent phosphate transporter PIT-1 and by inhibition of NF-κB activation and the subsequent BMP2/p-SMAD pathway. Pulse pressure, a marker of arterial stiffness, was significantly decreased in VDN animals treated with CBF. In line with our preclinical data, CBF concentration is significantly reduced in diseases characterized by increased calcification, as shown in patients with chronic kidney disease. In preparation for clinical translation, the active site of the native 19-AS long native CBF was identified as EGQEEEED. In conclusion, we have identified the new peptide CBF, which is secreted from the adrenal glands and might prevent vascular calcification by inhibition of osteogenic transdifferentiation. The anti-calcific effects of CBF and short active site may therefore promote the development of new tools for the prevention and/or treatment of vascular calcification. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00395-021-00899-z. Springer Berlin Heidelberg 2021-10-13 2021 /pmc/articles/PMC8514386/ /pubmed/34647168 http://dx.doi.org/10.1007/s00395-021-00899-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Contribution Orth-Alampour, Setareh Gayrard, Nathalie Salem, Silvia Bhargava, Shruti Jankowski, Vera Jover, Bernard Notarnicola, Cécile Noels, Heidi van der Vorst, Emiel P. C. Kuppe, Christoph Wolf, Michael Goettsch, Claudia Theelen, Wendy Bruck, Heike Fliser, Danilo Loscalzo, Joseph Wu, Zhuojun Marx, Nikolaus Zidek, Walter Argilés, Àngel Jankowski, Joachim Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation |
title | Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation |
title_full | Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation |
title_fullStr | Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation |
title_full_unstemmed | Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation |
title_short | Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation |
title_sort | prevention of vascular calcification by the endogenous chromogranin a-derived mediator that inhibits osteogenic transdifferentiation |
topic | Original Contribution |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514386/ https://www.ncbi.nlm.nih.gov/pubmed/34647168 http://dx.doi.org/10.1007/s00395-021-00899-z |
work_keys_str_mv | AT orthalampoursetareh preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT gayrardnathalie preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT salemsilvia preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT bhargavashruti preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT jankowskivera preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT joverbernard preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT notarnicolacecile preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT noelsheidi preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT vandervorstemielpc preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT kuppechristoph preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT wolfmichael preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT goettschclaudia preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT theelenwendy preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT bruckheike preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT fliserdanilo preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT loscalzojoseph preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT wuzhuojun preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT marxnikolaus preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT zidekwalter preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT argilesangel preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation AT jankowskijoachim preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation |